Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Debiopharm International SA
With
Phase 1, multi-center, open-label, dose-escalation study to: * Evaluate the safety profile and MTD of RP-6306 with gemcitabine to establish the RP2D and schedule * Characterize the PK and pharmacodynamics of RP-6306 with gemcitabine * Assess preliminary anti-tumor activity associated with RP-6306 with gemcitabine The Sponsor of the study has changed from 'Repare Therapeutics' to 'Debiopharm International SA' in the United States.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted